Report overview
Epilepsy is associated with disrupted activities in the brain called seizures, which affects the central nervous system. Depending on the area of the brain obstructed by seizures, these are categorized into generalized seizures and partial seizures. Generalized seizures affect the whole brain, while partial seizures affect just one part of the brain. Depending on their severity, seizures are termed as mild seizures and stronger seizures. Mild seizures are difficult to diagnose, as these last for only a few seconds. Stronger seizures may last for a few seconds to a few or several minutes, resulting in spasms and uncontrollable muscle twitches. This may cause the patient to lose consciousness, lead to temporary loss of cognition, or memory loss during the seizure. Pediatric epilepsy can be caused due to a trauma injury, complications during birth, or genetic disorder. Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while genetics related condition is called idiopathic epilepsy.
This report aims to provide a comprehensive presentation of the global market for Anti-epileptic Drugs for Pediatrics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-epileptic Drugs for Pediatrics. This report contains market size and forecasts of Anti-epileptic Drugs for Pediatrics in global, including the following market information:
Global Anti-epileptic Drugs for Pediatrics Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Anti-epileptic Drugs for Pediatrics Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Anti-epileptic Drugs for Pediatrics companies in 2022 (%)
The global Anti-epileptic Drugs for Pediatrics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
1st Generation Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Anti-epileptic Drugs for Pediatrics include Mylan N.V, Cephalon, Inc, GlaxoSmithKline plc, Janssen Pharmaceuticals, Novartis AG, Pfizer, Inc, Sanofi S.A, UCB Pharma Limited and Sunovion Pharmaceuticals Limited, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Anti-epileptic Drugs for Pediatrics manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Anti-epileptic Drugs for Pediatrics Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Anti-epileptic Drugs for Pediatrics Market Segment Percentages, by Type, 2022 (%)
1st Generation
2nd Generation
3rd Generation
Global Anti-epileptic Drugs for Pediatrics Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Anti-epileptic Drugs for Pediatrics Market Segment Percentages, by Application, 2022 (%)
Hospitals
Retail Pharmacies
Online Pharmacies
Global Anti-epileptic Drugs for Pediatrics Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Anti-epileptic Drugs for Pediatrics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Anti-epileptic Drugs for Pediatrics revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Anti-epileptic Drugs for Pediatrics revenues share in global market, 2022 (%)
Key companies Anti-epileptic Drugs for Pediatrics sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Anti-epileptic Drugs for Pediatrics sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Mylan N.V
Cephalon, Inc
GlaxoSmithKline plc
Janssen Pharmaceuticals
Novartis AG
Pfizer, Inc
Sanofi S.A
UCB Pharma Limited
Sunovion Pharmaceuticals Limited
Valeant Pharmaceuticals International, Inc
Zogenix
GW Pharmaceuticals
Insys
Zynerba
Outline of Major Chapters:
Chapter 1: Introduces the definition of Anti-epileptic Drugs for Pediatrics, market overview.
Chapter 2: Global Anti-epileptic Drugs for Pediatrics market size in revenue and volume.
Chapter 3: Detailed analysis of Anti-epileptic Drugs for Pediatrics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Anti-epileptic Drugs for Pediatrics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Anti-epileptic Drugs for Pediatrics capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
